Xencor (XNCR) Cash from Investing Activities (2013 - 2026)
Xencor (XNCR) posted quarterly Cash from Investing Activities of $26.7 million for Q1 2026, up 95.18% year-over-year from $13.7 million in Q1 2025, and down 62.52% quarter-over-quarter from $71.2 million in Q4 2025.
Analysis
Xencor (XNCR) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Cash from Investing Activities for 14 consecutive years, with $26.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 95.18% year-over-year to $26.7 million; the TTM figure through Mar 2026 stood at $153.0 million (up 676.86% YoY), while the FY2025 annual figure was $140.0 million, up 1878.26% from the prior year.
- Cash from Investing Activities slipped to $26.7 million in Q1 2026 per XNCR's latest filing, from $71.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $71.2 million in Q4 2025 and bottomed at -$203.1 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged -$4.2 million across 5 years, with a median of $24.5 million in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 927.48% — and 2024, when it jumped 4798.65%.
- Xencor's Cash from Investing Activities stood at $24.5 million in 2022, then plunged by 927.48% to -$203.1 million in 2023, then surged by 128.18% to $57.3 million in 2024, then gained by 24.32% to $71.2 million in 2025, then plunged by 62.52% to $26.7 million in 2026.
- Business Quant data shows XNCR's Cash from Investing Activities at $26.7 million in Q1 2026, $71.2 million in Q4 2025, and $14.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 85.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.12 Mn |
| Mar 31, 2026 | 26.68 Mn |
| Dec 31, 2025 | 71.17 Mn |
| Sep 30, 2025 | 14.67 Mn |
| Jun 30, 2025 | 40.48 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Dec 31, 2024 | 57.25 Mn |
| Sep 30, 2024 | -163.46 Mn |
| Jun 30, 2024 | 66.02 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Dec 31, 2023 | -203.13 Mn |
| Sep 30, 2023 | 45.33 Mn |
| Jun 30, 2023 | -1.41 Mn |
| Mar 31, 2023 | 48.14 Mn |
| Dec 31, 2022 | 24.55 Mn |
| Sep 30, 2022 | 3.13 Mn |
| Jun 30, 2022 | -75.64 Mn |
| Mar 31, 2022 | -71.76 Mn |
| Dec 31, 2021 | 7.86 Mn |
| Sep 30, 2021 | -38.85 Mn |